• Molecular NameNaringin
  • SynonymNA
  • Weight580.539
  • Drugbank_IDN/A
  • ACS_NO10236-47-2
  • Show 3D model
  • LogP (experiment)-0.44
  • LogP (predicted, AB/LogP v2.0)-0.51
  • pkaN/A
  • LogD (pH=7, predicted)-0.51
  • Solubility (experiment)1 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.19
  • LogSw (predicted, AB/LogsW2.0)1.3
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors8
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds6
  • TPSA225.06
  • StatusN/A
  • AdministrationN/A
  • PharmacologyNaringin exerts a variety of pharmacological effects such as antioxidant activity, blood lipid lowering, anticancer activity, and inhibition of selected drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug interactions in vivo.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability20.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A